Point-Of-Care Testing (POCT) Market Size, Share, Growth, and Industry Analysis, By Types (Blood Glucose Testing, Infectious Diseases Testing, Cardiac Markers Testing, Coagulation Testing, Pregnancy and Fertility Testing, Blood Gas/Electrolytes Testing, Urinalysis Testing), By Applications (Clinics, Hospitals, Laboratory, Others), and Regional Insights and Forecast to 2035

Point-Of-Care Testing (POCT) Market Size

The Global Point-Of-Care Testing (POCT) Market size was USD 260.98 Million in 2025 and is projected to touch USD 286.99 Million in 2026 and USD 315.61 Million in 2027, reaching USD 675.07 Million by 2035, exhibiting a CAGR of 9.97% during the forecast period from 2026 to 2035.

The Point-Of-Care Testing (POCT) Market is advancing as healthcare providers move diagnostic decision-making closer to patients and prioritize faster clinical intervention. Approximately 64% of demand is associated with rapid-testing workflows in hospitals, clinics, emergency settings, and decentralized care locations, while nearly 42% of purchasing decisions increasingly consider connectivity, automated result transfer, compact instrumentation, and simplified operator workflows.

In the US Point-Of-Care Testing (POCT) Market, adoption is supported by decentralized healthcare delivery, chronic disease monitoring, urgent-care expansion, and demand for rapid infectious-disease diagnostics. Approximately 69% of large acute-care facilities use multiple point-of-care testing categories, while nearly 47% of diagnostic modernization programs emphasize connected instruments capable of transferring patient results into digital clinical workflows.

The Point-Of-Care Testing (POCT) Market combines portable analyzers, disposable cartridges, lateral-flow technologies, molecular diagnostics, biosensors, and connected testing platforms. Nearly 58% of current product-development activity focuses on reducing workflow complexity, while approximately 36% emphasizes multiplexing, digital connectivity, or broader testing menus that enable healthcare professionals to obtain actionable information closer to the patient.

Key Findings

• Market Size: Valued at USD 286.99 Million in 2026 and USD 315.61 Million in 2027, the market is projected to reach USD 675.07 Million by 2035, exhibiting a CAGR of 9.97%.
• Growth Drivers: Decentralized diagnostics, chronic disease management, and faster clinical decisions support expansion, with approximately 62% of healthcare testing programs emphasizing reduced result turnaround.
• Trends: Connected analyzers and multiplex testing are becoming increasingly important, with nearly 44% of advanced POCT procurement programs considering interoperability or automated data-transfer capabilities.
• Key Players: Abbott, Roche, Siemens Healthcare, Danaher, and Bio-Rad Laboratories maintain substantial market visibility, with leading suppliers benefiting from broad diagnostic portfolios and installed instrument networks.
• Regional Insights: North America represents approximately 36%, Europe 25%, Asia-Pacific 30%, and Middle East & Africa 9% of global market activity.
• Challenges: Quality assurance, operator variability, reimbursement complexity, and device standardization remain important constraints, affecting approximately 31% of decentralized testing implementation programs.
• Industry Impact: Rapid testing can shorten diagnostic pathways, with nearly 54% of high-acuity POCT users prioritizing faster treatment decisions and reduced dependence on centralized laboratory turnaround.
• Recent Developments: Approximately 41% of competitive product initiatives emphasize expanded assay menus, multiplex detection, connectivity, or simplified near-patient workflows.

Point-of-care diagnostics are moving beyond single-purpose rapid tests toward connected clinical platforms. Approximately 46% of emerging system requirements incorporate data-management capabilities, while nearly 34% emphasize multi-analyte testing, reflecting the growing importance of combining diagnostic speed with stronger workflow integration.

Competitive differentiation increasingly depends on assay accuracy, compact hardware, cartridge simplicity, connectivity, and testing-menu breadth. Nearly 52% of institutional buyers place workflow efficiency among major procurement considerations, while approximately 39% prioritize instruments that can operate across multiple decentralized clinical environments.

Point-Of-Care Testing (POCT) Market Trends

The Point-Of-Care Testing (POCT) Market is shifting toward decentralized, digitally connected diagnostics that support clinical decisions during the patient encounter. Healthcare systems increasingly favor compact analyzers capable of delivering laboratory-comparable information without transporting every sample to a central facility. Approximately 61% of institutional POCT demand is influenced by faster turnaround requirements, while nearly 43% of advanced purchasing programs include connectivity or automated result-management considerations. Blood glucose remains deeply embedded in near-patient workflows, but infectious disease, cardiac marker, blood gas, electrolyte, coagulation, and urinalysis testing are widening the addressable clinical base. Manufacturers are consequently designing platforms around simplified cartridges, smaller sample volumes, reduced manual preparation, and intuitive interfaces. This transition is especially visible in emergency departments, intensive-care environments, physician offices, urgent-care centers, and community health facilities where diagnostic speed can materially alter patient routing and treatment decisions.

Multiplexing and digital integration represent another structural trend in the Point-Of-Care Testing (POCT) Market. Approximately 38% of emerging molecular POCT initiatives involve simultaneous detection of multiple diagnostic targets, while nearly 45% of healthcare organizations evaluating next-generation systems consider interoperability with clinical information infrastructure. Manufacturers are also investing in quality-control automation, wireless communication, cybersecurity, cloud-supported device management, and operator identification. These features address a central challenge of decentralized testing: maintaining laboratory-grade governance when instruments are distributed across many departments and operated by diverse healthcare personnel. Product design is therefore evolving from isolated test devices toward integrated diagnostic ecosystems. Growing home-linked care models and community testing are also encouraging development of smaller systems with easier specimen handling and fewer procedural steps, broadening the potential use of POCT beyond conventional hospital environments.

Point-Of-Care Testing (POCT) Market Dynamics

OPPORTUNITY

Expansion of decentralized and connected diagnostic pathways

Healthcare delivery outside centralized laboratories creates a substantial opportunity for portable diagnostic platforms. Approximately 48% of emerging POCT opportunities are associated with urgent care, physician offices, community facilities, outpatient pathways, or distributed hospital departments, while nearly 37% involve digitally connected testing. Manufacturers can capture additional demand by combining compact instruments with broader assay menus, automated quality control, wireless result transmission, and straightforward cartridge workflows. Molecular testing offers particularly strong potential as multiplex technologies allow clinicians to differentiate clinically similar infections during a single encounter. Expansion into underserved settings also creates opportunities for devices requiring limited laboratory infrastructure, minimal specimen preparation, and simplified staff training.

DRIVERS

Need for faster clinical decisions and chronic disease monitoring

Demand for rapid actionable diagnostic information remains the principal growth driver. Approximately 66% of high-acuity POCT utilization is linked to situations where shortened turnaround can influence treatment, triage, monitoring, or patient disposition, while nearly 49% of recurring decentralized testing demand is associated with chronic or frequently monitored conditions. Hospitals increasingly deploy near-patient testing across emergency, critical-care, surgical, and specialist settings to reduce delays between sample collection and clinical action. Diabetes monitoring maintains a large installed base, while infectious disease, blood gas, electrolyte, coagulation, and cardiac testing broaden utilization. Easier operation and smaller sample requirements further support adoption among clinical teams outside central laboratories.

Market Restraints

"Quality-control requirements and inconsistent decentralized workflows"

Decentralization introduces operational complexity because POCT instruments may be distributed across numerous departments and operated by personnel with different training levels. Approximately 32% of healthcare organizations identify quality management and operator competency as important barriers to broader deployment, while nearly 27% report integration or standardization concerns. Incorrect specimen handling, inconsistent calibration procedures, connectivity gaps, and weak governance can reduce confidence in decentralized testing. Institutions therefore require structured training, external quality assessment, operator-lockout capabilities, and centralized device management. These requirements can slow adoption among smaller facilities with limited laboratory oversight, particularly when multiple instrument brands and assay formats must be managed simultaneously.

Market Challenges

"Balancing diagnostic speed with accuracy, affordability, and interoperability"

The central challenge for POCT manufacturers is delivering rapid results without compromising analytical reliability or increasing workflow complexity. Approximately 35% of purchasing evaluations place total testing efficiency alongside analytical performance, while nearly 29% identify interoperability as a significant implementation issue. Devices must function consistently across variable environmental conditions, operators, specimen types, and patient populations. Manufacturers also face pressure to broaden assay menus without increasing cartridge complexity or instrument footprint. Cybersecurity and data integrity are becoming additional considerations as connected analyzers communicate with hospital systems. Companies capable of combining robust quality controls, intuitive interfaces, reliable connectivity, and scalable consumable supply are better positioned to address these operational challenges.

Segmentation Analysis

The Point-Of-Care Testing (POCT) Market is segmented across rapid metabolic monitoring, infectious-disease diagnosis, cardiovascular assessment, coagulation management, reproductive testing, critical-care analysis, and urinalysis. Blood glucose testing accounts for approximately 27% of type-related demand, while infectious diseases testing represents nearly 22%, reflecting the combined importance of recurring chronic-disease monitoring and rapid pathogen identification. Application demand is distributed across hospitals, clinics, laboratories, and other decentralized environments.

By Type

Blood Glucose Testing

Blood glucose testing represents approximately 27% of type-based POCT demand and remains one of the most established decentralized diagnostic categories. Nearly 63% of institutional glucose-testing utilization occurs through recurring monitoring workflows where rapid results support medication, nutrition, and treatment decisions. Connected meters, improved strip performance, automated patient identification, and digital result transmission are strengthening hospital and clinic adoption while reducing manual documentation requirements.

Infectious Diseases Testing

Infectious diseases testing represents nearly 22% of type-based activity as healthcare providers increasingly seek rapid differentiation of respiratory, gastrointestinal, and other communicable infections. Approximately 46% of advanced infectious-disease POCT demand is moving toward molecular or multiplex approaches. Faster pathogen identification can improve isolation decisions, antimicrobial selection, and patient routing while supporting broader adoption across urgent-care centers, clinics, emergency departments, and community healthcare settings.

Cardiac Markers Testing

Cardiac markers testing accounts for approximately 13% of type-based demand and is strongly associated with emergency and acute-care workflows. Nearly 57% of usage concentrates on situations where rapid biomarker information can support faster cardiovascular assessment. Portable cardiac testing helps clinicians evaluate suspected myocardial injury closer to the patient while reducing dependence on sample transportation, making turnaround efficiency, analytical sensitivity, and standardized cartridge performance important purchasing considerations.

Coagulation Testing

Coagulation testing contributes approximately 10% of type-based POCT demand, supported by anticoagulation management, surgical care, and emergency medicine. Around 48% of decentralized coagulation use is associated with recurring patient-management or procedure-related testing. Portable systems allow clinicians to obtain coagulation information without lengthy sample transportation, supporting faster treatment adjustments while creating demand for reliable quality controls, standardized reagents, compact analyzers, and connectivity with clinical records.

Pregnancy and Fertility Testing

Pregnancy and fertility testing represents approximately 9% of type-related POCT activity and benefits from established lateral-flow formats and straightforward interpretation. Approximately 72% of testing demand favors simple disposable formats that require limited instrumentation. Clinics, physician practices, pharmacies, and other decentralized environments value rapid reproductive-health testing because it provides immediate information and supports same-visit clinical decisions while maintaining relatively simple specimen handling and operational requirements.

Blood Gas/Electrolytes Testing

Blood gas and electrolyte testing accounts for approximately 12% of type-based demand and remains essential in intensive care, emergency medicine, operating rooms, and neonatal care. Nearly 61% of utilization occurs in high-acuity environments where rapid physiological assessment can influence immediate treatment. Portable analyzers with small sample requirements, multi-analyte cartridges, and fast processing are increasingly preferred for critically ill patients and time-sensitive clinical pathways.

Urinalysis Testing

Urinalysis testing represents approximately 7% of type-based POCT demand and serves primary care, emergency medicine, chronic disease monitoring, and routine screening. Nearly 54% of decentralized urinalysis activity uses simplified strip-based or compact reader workflows. Automated interpretation, standardized optical reading, and digital documentation are gradually replacing subjective visual assessment, helping improve consistency while maintaining the speed and operational simplicity expected from point-of-care testing.

By Application

Clinics

Clinics account for approximately 24% of application demand as physician offices and urgent-care facilities increasingly perform diagnostics during the patient visit. Nearly 49% of clinic-based POCT utilization involves infectious disease, glucose, pregnancy, or routine rapid testing. Compact instruments with limited maintenance requirements are particularly attractive because they allow smaller clinical teams to generate actionable results without maintaining extensive central laboratory infrastructure.

Hospitals

Hospitals represent approximately 48% of application demand and remain the largest institutional environment for POCT deployment. Around 67% of hospital utilization concentrates in emergency, intensive-care, surgical, inpatient, or other time-sensitive settings. Hospitals increasingly require networked instruments, centralized quality management, operator identification, and automatic result transmission because hundreds of decentralized devices may operate across a single healthcare network.

Laboratory

Laboratory applications represent approximately 18% of demand, particularly where satellite laboratories and rapid-response diagnostic units support decentralized clinical pathways. Nearly 42% of laboratory-linked POCT programs focus on coordinating near-patient instruments with central quality-management processes. Laboratories remain influential in device validation, operator competency, calibration, quality assurance, and result governance, creating demand for systems that provide strong analytical traceability and centralized monitoring capabilities.

Others

Other applications account for approximately 10% of demand and include community health facilities, pharmacies, mobile healthcare environments, occupational testing locations, and specialized decentralized settings. Approximately 38% of emerging activity in this category is associated with portable or low-infrastructure diagnostic models. Easy specimen collection, minimal preparation, compact equipment, and simplified training are particularly important for extending diagnostic access beyond conventional hospitals and laboratories.

Point-Of-Care Testing (POCT) Market Regional Outlook

The regional Point-Of-Care Testing (POCT) Market reflects differences in healthcare infrastructure, decentralized care adoption, diagnostic accessibility, and clinical technology investment. North America accounts for approximately 36% of global demand, followed by Asia-Pacific at 30%, Europe at 25%, and Middle East & Africa at 9%. Regional competition increasingly centers on connected platforms, assay availability, regulatory compliance, and access to recurring consumables.

North America

North America holds approximately 36% of the global Point-Of-Care Testing (POCT) Market, supported by extensive hospital adoption, urgent-care networks, chronic disease monitoring, and decentralized molecular diagnostics. Nearly 58% of advanced institutional procurement programs in the region consider connectivity or automated result management important. Strong utilization across emergency medicine, critical care, diabetes management, and respiratory diagnostics continues to support demand for compact and multiplex platforms.

Europe

Europe accounts for approximately 25% of global market activity, supported by established healthcare systems and increasing use of near-patient diagnostics across hospitals and community settings. Approximately 44% of regional modernization initiatives emphasize workflow standardization or digital integration. Demand is particularly visible in glucose management, blood gas analysis, coagulation, infectious disease diagnostics, and primary-care testing, while quality assurance remains central to procurement decisions.

Asia-Pacific

Asia-Pacific represents approximately 30% of global demand and benefits from expanding healthcare infrastructure, diagnostic decentralization, and improving access to rapid testing. Nearly 51% of emerging regional opportunities are associated with expanding hospital, outpatient, community, or primary-care diagnostic capacity. Large patient populations and rising chronic-disease testing requirements support glucose and cardiovascular applications, while infectious-disease diagnostics create additional demand for portable molecular and immunoassay technologies.

Middle East & Africa

Middle East & Africa accounts for approximately 9% of the global Point-Of-Care Testing (POCT) Market. Approximately 43% of regional growth opportunities are linked to expanding diagnostic accessibility outside large centralized laboratories. Portable devices requiring limited infrastructure can support emergency medicine, primary care, maternal health, infectious-disease testing, and chronic disease monitoring, while procurement programs increasingly prioritize durable systems, simplified consumables, and straightforward staff training.

List of Key Point-Of-Care Testing (POCT) Market Companies Profiled

Investment Analysis and Opportunities in Point-Of-Care Testing (POCT) Market

Investment activity in the Point-Of-Care Testing (POCT) Market is increasingly directed toward molecular miniaturization, biosensors, connected diagnostic ecosystems, cartridge automation, and decentralized care. Approximately 39% of strategic development investment is concentrated on technologies capable of shortening sample-to-result workflows, while nearly 34% targets connectivity, informatics, automation, or remote device management. Attractive opportunities exist in multiplex infectious-disease testing, cardiovascular biomarkers, critical-care analysis, and diagnostic platforms suited to clinics and community environments. Companies are also investing in manufacturing scalability because recurring cartridges and test consumables are central to platform utilization. Partnerships between diagnostic manufacturers, digital-health developers, healthcare networks, and technology specialists are likely to expand as buyers increasingly expect integrated devices rather than isolated testing instruments.

New Products Development

New product development is focused on smaller instruments, broader test menus, reduced specimen requirements, faster workflows, and improved digital connectivity. Approximately 42% of next-generation development programs emphasize multiplex or multi-analyte capability, while nearly 37% incorporate enhanced connectivity or automated data handling. Molecular POCT is becoming particularly important because compact PCR-based systems can provide pathogen differentiation close to patients. Manufacturers are simultaneously refining blood gas, electrolyte, glucose, cardiac, coagulation, and urinalysis systems through simplified cartridges and automated quality controls. Product teams increasingly design interfaces around non-laboratory operators, reducing manual processing steps and supporting guided workflows. Integration with clinical information systems is also becoming a core design requirement as healthcare organizations seek consistent governance across distributed testing networks.

Recent Developments

• January 2025– Roche expanded molecular point-of-care testing: Roche received regulatory clearance and waiver status for cobas liat multiplex testing for sexually transmitted infections, strengthening decentralized molecular diagnostics. The development supports a broader shift toward same-visit testing, with approximately 45% of advanced molecular POCT demand increasingly associated with multiplex or differentiated pathogen detection.

• April 2024– Quidel expanded QuickVue rapid testing: Quidel received regulatory clearance for its QuickVue COVID-19 test for home and qualified medical-facility use. Rapid infectious-disease formats remain important within decentralized diagnostics, where approximately 41% of users prioritize simple workflows capable of supporting testing outside traditional centralized laboratories.

• June 2024– BioMerieux expanded BIOFIRE SPOTFIRE testing: BioMerieux received regulatory clearance and waiver status for the BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini, extending multiplex molecular testing at the point of care. Approximately 38% of emerging infectious-disease POCT development is associated with multiplex approaches designed to distinguish multiple clinically similar pathogens.

• 2025– Quidel strengthened diagnostic informatics capabilities: Quidel introduced an enhanced results-management approach designed to improve diagnostic information workflows across its broader portfolio. Connectivity is becoming increasingly relevant to decentralized diagnostics, with approximately 44% of institutional POCT procurement programs considering electronic result transfer, workflow management, or interoperability during platform evaluation.

• 2025– Abbott advanced rapid diagnostic workflow development: Abbott continued expanding rapid diagnostic capabilities across its testing portfolio, reinforcing demand for faster biomarker assessment and streamlined clinical workflows. Approximately 40% of advanced near-patient development priorities now focus on reducing analytical turnaround or specimen-handling complexity, particularly in emergency and high-acuity healthcare environments.

Report Coverage

The Point-Of-Care Testing (POCT) Market report evaluates competitive structure, technology development, market dynamics, segmentation, regional demand, investment priorities, and product innovation across the diagnostic ecosystem. Type analysis covers blood glucose testing, infectious diseases testing, cardiac markers testing, coagulation testing, pregnancy and fertility testing, blood gas/electrolytes testing, and urinalysis testing, with blood glucose representing approximately 27% and infectious diseases testing nearly 22% of type-based demand. Application coverage examines clinics, hospitals, laboratories, and other decentralized healthcare settings, with hospitals accounting for approximately 48% of application activity. Regional assessment covers North America, Europe, Asia-Pacific, and Middle East & Africa, representing 36%, 25%, 30%, and 9% respectively. The competitive analysis includes established diagnostic manufacturers across portable analyzers, rapid assays, molecular platforms, blood analysis systems, glucose monitoring, and connected diagnostic solutions. Coverage also evaluates decentralization, chronic disease monitoring, infectious-disease testing, multiplex technology, interoperability, operator management, quality assurance, cartridge-based workflows, and digital connectivity as major factors influencing the evolving Point-Of-Care Testing (POCT) Market.